Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elesclomol with Paclitaxel and Carboplatin in NSCLC
NCT00088088Phase 2Completed
- Sponsor
- Synta Pharmaceuticals Corp.
- Start
- Mar 2004
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of elesclomol in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Synta Pharmaceuticals Corp. Primary endpoints: Maximum Tolerated Dose, Progression-Free Survival up to 1 year and 1 more. Started Mar 2004; status: completed.
02
Drugs
elesclomol
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00088088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00088088.